Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT03841110 | FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | PHASE1 | COMPLETED | 37 | — | — | Feb 15, 2019 | Nov 15, 2022 | May 1, 2023 | 4 | United States |
The incidence of participants with DLTs within each assessed dose level cohort to determine the maximum tolerated dose (MTD) or maximum assessed dose (MAD).
| Arm | Type | Description |
|---|---|---|
| FT500 Monotherapy | EXPERIMENTAL | FT500 administered once weekly for 3 weeks as a monotherapy |
| FT500 in Combination with Immune Checkpoint Inhibitor | EXPERIMENTAL | FT500 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab. |
| FT500 +IL-2 in Combination with Immune Checkpoint Inhibitor | EXPERIMENTAL | FT500 + IL-2 administered once weekly for 3 weeks in combination with one of the following immune checkpoint inhibitors: nivolumab, pembrolizumab or atezolizumab. |
| Name | Type | Description |
|---|---|---|
| FT500 | DRUG | FT500 is an allogeneic, iPSC-derived Natural Killer (NK) cell cancer immunotherapy |
| Nivolumab | DRUG | Immune Checkpoint Inhibitor |
| Pembrolizumab | DRUG | Immune Checkpoint Inhibitor |
| Atezolizumab | DRUG | Immune Checkpoint Inhibitor |
| Cyclophosphamide | DRUG | Lympho-conditioning agent |
| Fludarabine | DRUG | Lympho-conditioning agent |
| IL-2 | DRUG | Biologic response modifier |
Inclusion Criteria: 1\. Diagnosis of the following, as per Regimen Cohort: 1A. Regimen A: FT500 Monotherapy (Dose Escalation): An advanced solid tumor malignancy, including lymphoma, in a participant who has failed or refused available FDA-approved therapies and is now a candidate for salvage ther...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |